# Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia

> **NCT01059786** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 69 (actual)

## Conditions studied

- Hairy Cell Leukemia

## Interventions

- **DRUG:** Pentostatin
- **DRUG:** Rituximab
- **DRUG:** Bendamustine
- **DRUG:** Acetaminophen
- **DRUG:** Diphenhydramine
- **DRUG:** Epinephrine
- **DRUG:** Antihistamines
- **DRUG:** Corticosteroids
- **DRUG:** Bronchodilators
- **OTHER:** Intravenous (IV) Saline

## Key facts

- **NCT ID:** NCT01059786
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2010-07-01
- **Primary completion:** 2022-12-15
- **Final completion:** 2027-12-31
- **Target enrollment:** 69 (ACTUAL)
- **Last updated:** 2025-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01059786

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01059786, "Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT01059786. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*